Drug Database
PA

pancrelipase (Ultrase MT20 / Ultrase MT / Ultresa)

✓ Approved

Adare Pharma Solutions · PNLIP

What is pancrelipase?

pancrelipase is a therapeutic agent developed by Adare Pharma Solutions. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesUltrase MT20, Ultrase MT, Ultresa
CompanyAdare Pharma Solutions
Molecular TargetPNLIP
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

pancrelipase acts on 1 molecular target:

PNLIPpancreatic lipase (PL, PNLIPD)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pancrelipase is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
InvestigationsFaecal fat increased✓ Approved
Gastrointestinal disordersSteatorrhoea✓ Approved
Gastrointestinal disordersPancreatic failure✓ Approved

Related Research Articles

PubMedWellcome open research2026-09-19

Implementation of 7-1-7 for improving timeliness in outbreak detection and response in Thailand: A mixed-methods study on challenges in application and achievement of targets in 2024-25.

Watakulsin Peeriya P, Jitpeera Charuttaporn C, Promduangsi Pitiphon P, Yueayai Khanuengnij K et al.

Infectious disease outbreaks result in unfavourable outcomes when swift actions fail. The 7-1-7 target (detect within 7 days, notify within 1 day, respond within 7 days) was proposed to improve timeliness. Thailand piloted 7-1-7 in 2024 and scaled it up nationwide in 2025. This study aimed to quantify the 7-1-7 target achievement, identify bottlenecks and enablers, and describe challenges and solutions for applying the 7-1-7 metrics. A mixed-methods study was conducted with quantitative assessment of all events meeting the national health threat criteria during January 2024 and June 2025 for timeliness, bottlenecks and enablers for meeting the 7-1-7 target. A qualitative descriptive study with in-depth interviews of key stakeholders explored challenges and solutions for applying the 7-1-7 framework. Of the 1,435 events assessed, 15% were dangerous communicable diseases and 3% occurred in hotels. Among all the events, 50% achieved the 7-1-7 target; 85%, 73%, and 83% were detected, notified and responded to in a timely manner, respectively. The median (interquartile range) duration for detection, notification and response were 0 (0-5) days, 0 (0-2) days and 2 (0-5) days, respectively. Among events that occurred in hotels, none met the 7-1-7 target. Dangerous communicable diseases had the highest notification (95%) and response performance (99%), despite lower timely detection (71%). Key bottlenecks included delayed care-seeking and weak coordination. Key stakeholders felt that the 7-1-7 metrics was useful, but the lack of standardised data sources, disease-specific guidelines and centralised data extraction made implementation difficult. Proposed solutions focused on streamlining and decentralizing the application of 7-1-7. It is appreciable that Thailand was able to apply the 7-1-7 framework and half of the events met the 7-1-7 target. However, to better the application of 7-1-7, future work should focus on strengthening data integration and formulating disease specific guidelines.

PubMedHealth communication2026-09-19

"They Call Us Cheaters": Exploring Stigma Management Communication Strategies During GLP-1 Medication Use.

Lazenby Braidyn B, Guidry Ashley A, Price Sarah S, Shuvo Md Sazzad Mahmud MSM et al.

As GLP-1 receptor agonist medications become more popular, conversations surrounding the medication's use are becoming increasingly more complicated. Emerging research suggests that individuals taking these medications often feel stigmatized. However, understanding how individuals manage stigma through communication is less explored. Using stigma management communication theory, the current study seeks to better understand how individuals communicatively manage stigma surrounding GLP-1 medication use. A reflexive thematic analysis of interviews with GLP-1 users (n = 34) suggests that individuals evaluate their interpretations of both their own self-stigma and the public's understanding of GLP-1 and engage in various different stigma management communication strategies in response. These strategies, while effective for stigma management, may inadvertently contribute to ongoing stigmatizing discourse surrounding GLP-1 use.

PubMedbioRxiv : the preprint server for biology2026-09-19

Herpes simplex virus 1 subverts the mitochondrial network to support the infection: A lesson on mitochondrial versatility.

Saud Rabina R, Foster-Lemieur Kimberly K, Duguay Brett B, Swerdlow Russell R et al.

Herpes simplex virus 1 (HSV-1) infects approximately 67% of the population worldwide. It establishes lifelong reservoirs in sensory neurons and has been linked to several diseases including neuronal dysfunction. Disruption of mitochondrial homeostasis is a hallmark of HSV-1 infection, however a molecular understanding of these changes and their significance is not yet well defined. HSV-1 infection causes a UL12.5-dependent inhibition of mitochondrial biogenesis through the loss of mitochondrial DNA and mitochondrial transcription factors, PGC-1α (peroxisome proliferator-activated receptor-gamma co-activator) and TFAM (mitochondrial transcription factor). Conversely, UL12.5-independent mechanisms inhibit mitochondrial fusion by activating the OMA1 metallopeptidase that cleaves the inner mitochondrial membrane fusion protein OPA1 (optic atrophy protein 1) and by down-modulating the outer mitochondrial membrane fusion protein MFN2 (mitofusin 2). This inhibition of fusion results in a smaller mitochondrial network that clusters to perinuclear regions, likely supplying energy for viral replication and envelopment. The inner mitochondrial membrane protein TIM23 is also down-modulated during infection in a UL12.5-independent mechanism. Failure of the virus to promote these changes negatively impacts the infection. Despite these changes, mitochondria are protected from mitophagy due to the viral-induced degradation of several mitophagy adaptor proteins, whereby damaged mitochondrial components, including mitochondrial DNA, are extruded via extracellular vesicles. These mitochondrial changes still support functions necessary for HSV-1 infection. Basal cell respiration is preserved, while spare respiratory capacity and extracellular acidification rates increase, indicating glycolytic activity. Mitochondrial membrane potential is also preserved. Overall, our studies provide mechanistic insight into how HSV-1 impacts mitochondria, which could contribute to viral pathogenesis. Mitochondria are often referred to as the "powerhouse" of the cell because they are the main energy producers. Disruption of mitochondrial homeostasis is associated with multiple diseases and occurs after infection with pathogens such as HSV-1. By investigating the mechanism(s) by which HSV-1 disrupts mitochondrial homeostasis, we can better understand how HSV-1 causes pathogenesis. HSV-1 infection impacts mitochondrial homeostasis through disruption of four key processes, including: 1) inhibition of mitochondrial biogenesis and the generation of new mitochondria; 2) inhibition of mitochondrial fusion, which rescues reversibly damaged mitochondria; 3) sustaining mitochondrial fission, which removes damaged content; and 4) preventing mitophagy, which clears damaged mitochondria. UL12.5-dependent and UL12.5- independent events during HSV-1 infection disrupt mitochondrial homeostasis, redirecting mitochondrial resources towards progeny virus production. These changes cause irreversible damage to host cells, ultimately driving pathogenesis.

PubMedGut pathogens2026-09-19

Retraction Note: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor‑1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses.

Morgan Radwa N RN, Saleh Sarra E SE, Farrag Hala A HA, Aboulwafa Mohammad M MM

PubMedThe EMBO journal2026-09-19

The BRCA1 coiled-coil domain is dispensable for suppression of tandem duplications and tolerance of FANCM loss.

Nilavar Namrata M NM, Marin-Gonzalez Alberto A, Menghi Francesca F, Nguyen Daniel D et al.

BRCA1-linked cancers contain abundant ~10 kb 'Group 1' tandem duplications (TDs). Group 1 TDs form at a Tus/Ter replication-fork barrier in DNA-end resection-defective mouse embryonic stem (mES) cells lacking Brca1 exon 11. To elucidate how BRCA1 suppresses Group 1 TDs, we analyzed Brca1 coiled-coil (CC)-domain mutants-separation-of-function alleles impaired for homologous recombination (HR) through loss of PALB2-binding and RAD51-loading functions but competent for DNA-end resection. Notably, Brca1 CC mutants retain the ability to suppress Group 1 TDs in the Tus/Ter system and in a mouse model of Brca1-linked mammary tumorigenesis. These data suggest that Brca1 CC domain-mutant cancers follow a path of tumorigenesis distinct from that of other Brca1-linked cancers. FANCM is a TD co-suppressor, loss of which is synthetic lethal/sick in Brca1 exon 11-deleted cells. In contrast, Fancm deletion unexpectedly improves the growth of Brca1 CC mutant and Brca2 mutant mES cells. Thus, Group 1 tandem duplication formation and Fancm synthetic lethality are linked phenotypes, potentially related to defective BRCA1-mediated DNA end resection but genetically separable from BRCA1/PALB2-mediated RAD51 loading.

PubMedJournal of nephrology2026-09-19

Graft Renal Vein Pulsatility as a Marker of Systemic Venous Congestion in Kidney Transplant Recipients: Concordance with the VExUS Score and Implications for Hemodynamic Management.

Sosa Barrios R Haridian RH, Vallejo María García MG, Vion Víctor M Burguera VMB, Lucas Milagros Fernández MF et al.

Bedside volume assessment after kidney transplantation is unreliable, and whether pulsatility of the graft renal vein in the denervated, encapsulated allograft reflects systemic venous congestion was unknown. We tested its association with the Venous Excess Ultrasound Score (VExUS). Prospective study of adult kidney transplant recipients assessed on days 1,7 and months 1,3. Pulsatility was categorised from continuous to discontinuous or reversed flow (≥30% threshold) and tested against VExUS-defined congestion by Fisher exact test, with exact confidence intervals and Cohen kappa; secondary analyses addressed bioimpedance (BIA), examination, delayed graft function and tacrolimus. Eighty-eight recipients were transplanted, 80 completing follow-up; denominators were 86, 85, 82 and 80. Pulsatility was associated with VExUS on days 1 and 7 and month 1 (all p<0.05), not month 3. On day 1, the ≥30% threshold gave specificity 88% (95% CI 78-95) and low sensitivity 42% (20-67) for VExUS ≥1; at >50%, 94% (85-98) and 26% (9-51). Chance-corrected agreement was the highest of any method pair (kappa 0.32, day 1). Discontinuous or reversed flow occurred in only three recipients on day 1, too few to estimate. Pulsatility was unrelated to BIA and tacrolimus. Graft renal vein pulsatility was associated with systemic venous congestion, supporting the transplanted vein as a functional equivalent of the native one. Retrograde pressure transmission into a rigid capsule is a plausible but unproven mechanism. Abnormal pulsatility rules congestion in but, because sensitivity is low, does not rule it out; interventional studies are needed before it guides management.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about pancrelipase